Foghorn Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity. The company has commenced a formal search for a successor. Dr. Reine?s last day as a full-time employee with Foghorn will be January 16, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.01 USD | -3.53% | +3.09% | -6.82% |
May. 20 | Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants | MT |
May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.82% | 333M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.64% | 22.78B | |
-10.74% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024